IQ EQ Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

IQ EQ Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.85M	Buy	2,557,403 +153,285	+6%	+$592K	0.6%	57
2025 Q4	$9.83M	Buy	2,404,118 +629,123	+35%	+$3.12M	0.68%	45
2025 Q3	$8.66M	Buy	1,774,995 +863,910	+95%	+$4.54M	0.59%	50
2025 Q2	$4.61M	Buy	911,085 +523,848	+135%	+$2.57M	0.41%	78
2025 Q1	$2.05M	Buy	387,237 +186,767	+93%	+$1.36M	0.24%	115
2024 Q4	$1.36M	Buy	200,470 +118,118	+143%	+$794K	0.16%	148
2024 Q3	$543K	Buy	82,352 +42,101	+105%	+$302K	0.06%	253
2024 Q2	$302K	Buy	+40,251	New	+$351K	0.03%	274

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IQ EQ Fund Management's RXRX Position: Q1 2026 in Review

IQ EQ Fund Management increased its Recursion Pharmaceuticals (RXRX) stake by 6.4% in Q1 2026, buying an estimated $592K and bringing the position to 2,557,403 shares worth $7.85M. The position accounts for 0.6% of the portfolio, ranked #57.

IQ EQ Fund Management first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $9.83M in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

IQ EQ Fund Management held 2,557,403 shares of Recursion Pharmaceuticals worth $7.85M as of Q1 2026.
IQ EQ Fund Management bought 153,285 Recursion Pharmaceuticals shares in Q1 2026, an estimated $592K.
Recursion Pharmaceuticals made up 0.6% of IQ EQ Fund Management's portfolio in Q1 2026, its #57 holding.
IQ EQ Fund Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
IQ EQ Fund Management's Recursion Pharmaceuticals position peaked at $9.83M in Q4 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on IQ EQ Fund Management's 13F filing for Q1 2026, filed 11 May 2026.